Skip to main content
  1. Home
  2. Products
  3. Companion Diagnostics
  4. PD-L1 IHC 28-8 pharmDx for SCCHN

PD-L1 IHC 28-8 pharmDx for SCCHN

More personalized cancer results. One test makes it possible.

PD-L1 IHC 28-8 pharmDx for SCCHN

The only CE-IVD test for PD-L1 expression associated with enhanced survival with OPDIVO® (nivolumab) for SCCHN1

Demonstrated clinical results

PD-L1 IHC 28-8 pharmDx is the first fully validated and clinically relevant test for OPDIVO in SCCHN.

Detection of PD-L1 expressing tumor cells in SCCHN patient specimens may indicate an enhanced survival benefit to OPDIVO (nivolumab) treatment for the patient.2

The CA209141 study demonstrated a statistically significant improvement in overall survival (OS) for subjects randomized to nivolumab as compared to investigator’s choice at a pre‑specified interim analysis (78% of the planned number of events for final analysis). The median OS was 7.5 months for nivolumab subjects compared to 5.1 months for investigator’s choice subjects with a hazard ratio (HR) of 0.70 (95% CI 0.53, 0.92).

Summary of OS by PD-L1 IHC 28-8 pharmDx expression level and treatment group1

Data from a pre-specified exploratory analysis (N=260) of CA209141 (N=361).

PD-L1 Expression <1% ≥1%
  Nivolumab Investigator’s Choice Nivolumab Investigator’s Choice
Median OS (95% CI) 5.7 mos. (4.4‑12.7) 5.8 mos. (4.0‑9.8) 8.7 mos. (5.7‑9.1) 4.6 mos. (3.8‑5.8)
Hazard Ratios 0.89 (95% CI: 0.54, 1.45) 0.55 (95% CI: 0.36, 0.83)
Abbreviations: CI = confidence interval

361 patients were randomized at 55 sites in 15 countries to one of two treatment arms (240 nivolumab vs. 121 to investigator’s choice) and stratified according to prior cetuximab treatment (yes/no). The major efficacy outcome measure for CA209141 was Overall Survival (OS). Additional efficacy outcome measures included Progression Free Survival (PFS) and Objective Response Rate (ORR).

Frequency of PD-L1 Expression in Quantifiable* Samples from SCCHN—CA2091411

PD-L1 Expression Nivolumab (N=161) Investigator’s Choice (N=99) Total (N=260)
≥1% PD-L1 Expression
Subjects		 88 (54.7%) 61 (61.6%) 149 (57.3%)
<1% PD-L1 Expression
Subjects		 73 (45.3%) 38 (38.4%) 111 (42.7%)
*327 of 361 samples were PD-L1 quantifiable from study CA209141.

Baseline SCCHN Specimen Origin—Study CA2091411

Tumor specimens were collected from SCCHN tumors from either a primary or metastatic site, consistent with the inclusion requirements for the study. 327 subjects (out of 361 total subjects) had tumor tissue collected at baseline with the following site proportion:

Primary Tumor

29.7%
(97/327)

Metastatic Tumor

52.0%
(170/327)

Not reported

18.3%
(60/327)

Robust performance

PD-L1 IHC 28-8 pharmDx is fully validated for analytical performance, having met stringent acceptance criteria for ultimate quality results.

Selected analytical
validation parameters		 Results for SCCHN
Analytical specificity
  • Demonstrated specificity to clone 28-8 for PD-L1 detection
  • PD-L1 primary antibody displays no cross-reactivity for PD-L2
  • Detection in normal tissues restricted to immune cells and infrequently to cells of epithelial origin
Sensitivity
  • Broad dynamic range of PD-L1 expression (0-95% of positive tumor cells, 0-3 staining intensity) exhibited in study of 236 unique cases of SCCHN FFPE specimen stages I to IV
Repeatability
  • Demonstrated lot-to-lot repeatability
  • 100% overall agreement for ≥1% expression level
External reproducibility
  • ≥97% overall agreement for ≥1% expression level
  • Reproducibility testing of day-to-day, site-to-site and observer-to-observer in a blinded study in three certified clinical labs
  • 95% confidence intervals from 88% to 100% agreement for both NPA and PPA
NPA = Negative Percent Agreement   |   PPA = Positive Percent Agreement

Order information

Product Code
PD-L1 IHC 28-8 pharmDx SK005
Required but not included in kit:  
Autostainer Link 48 AS480
EnVision FLEX Wash Buffer, 20x K8007
EnVision FLEX Hematoxylin (Link) K8008
PT Link PT101/PT200

References

  1. Clinical Trial: Checkmate 141, CA209141
  2. PD-L1 IHC 28-8 pharmDx Instructions for Use

Want to hear more about PD-L1 IHC 28-8 pharmDx?

Contact your local sales representative

CONTACT US

Product Information

Product details, specification sheet and safety data sheet (SDS).

PD-L1 IHC 28-8 pharmDx

Intended Use

For in vitro diagnostic use

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity, as defined by the specific tumor indication staining interpretation guidelines in the instructions for use (IFU).

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC and SCCHN may be associated with enhanced survival from OPDIVO (nivolumab).

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in melanoma may be used as an aid in the assessment of patients for whom OPDIVO (nivolumab) and YERVOY® (ipilimumab) combination treatment is being considered.2